-transparent.png){kind=logo}
Ifosfamide (1.25 g/m2 intravenously/day x 5) with mesna (20% of the ifosfamide dose x six doses on each day of ifosfamide therapy) was administered to 46 previously treated patients with non-Hodgkin's lymphoma of which 31 were eligible and evaluable. A 29% response rate (9/31) was observed (2 CR and 7 PR) with a median duration of response of 2.5 months. Myelosuppression was dose-limiting. Hemorrhagic cystitis was observed in three patients (10%). Nausea and vomiting was generally mild or moderate. One patient developed transient neurotoxic symptoms with confusion and disorientation. An additional patient developed an anaphylactic-type reaction with shortness of breath and respiratory strider during the fourth course of therapy. Ifosfamide, as a single agent, produces remissions of limited duration in non-Hodgkin's lymphoma in patients in second or third relapse.
D C Case, and
J Anderson, and
T J Ervin, and
A Gottlieb
May 1985,
Cancer treatment reports,
D C Case, and
J Anderson, and
T J Ervin, and
A Gottlieb
November 1989,
Investigational new drugs,
D C Case, and
J Anderson, and
T J Ervin, and
A Gottlieb
January 1993,
Medical and pediatric oncology,
D C Case, and
J Anderson, and
T J Ervin, and
A Gottlieb
October 1986,
Cancer treatment reports,
D C Case, and
J Anderson, and
T J Ervin, and
A Gottlieb
July 1993,
Cancer,
D C Case, and
J Anderson, and
T J Ervin, and
A Gottlieb
June 2000,
American journal of clinical oncology,
D C Case, and
J Anderson, and
T J Ervin, and
A Gottlieb
June 1994,
American journal of clinical oncology,
D C Case, and
J Anderson, and
T J Ervin, and
A Gottlieb
August 1996,
Annals of oncology : official journal of the European Society for Medical Oncology,
D C Case, and
J Anderson, and
T J Ervin, and
A Gottlieb
August 1998,
American journal of clinical oncology,
D C Case, and
J Anderson, and
T J Ervin, and
A Gottlieb
June 1987,
Cancer treatment reports,
